









市場行情
/
股票
/
nasdaq-cvac
/

CureVac NV

CVAC

4.300USD

-0.010-0.23%

收盤 12/26, 16:00（美東）報價延遲15分鐘

968.24M總市值

8.85本益比TTM



CureVac NV

4.300

-0.010-0.23%

概覽公司財務分析

概覽

公司

財務

分析

關於 CureVac NV 公司

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

CureVac NV簡介



公司代碼CVAC

公司名稱CureVac NV

上市日期Aug 14, 2020

CEOZehnder (Alexander)

員工數量825

證券類型Ordinary Share

年結日Aug 14

公司地址Friedrich-Miescher-Str. 15

城市TUEBINGEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Germany

郵編72076

電話49707198830

網址https://www.curevac.com/

公司代碼CVAC

上市日期Aug 14, 2020

CEOZehnder (Alexander)

CureVac NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

Dr. Malte Greune, Ph.D.

Chief Operating Officer, Member of the Management Board

Dr. Debra Barker, M.D.

Member of the Supervisory Board

Dr. Alexander Zehnder, M.D.

Chief Executive Officer, Member of the Management Board

Dr. Myriam Mendila, M.D.

Chief Scientific Officer, Member of the Management Board

名稱

名稱/職務

職務

持股

持股變動

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

Switzerland

1.06M

85.06%

Belgium (Country)

186.00K

14.94%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月16日週二

持股股東

股東類型

持股股東

佔比

Glazer Capital, LLC

2.02%

Alpine Associates Management Inc.

1.02%

Qube Research & Technologies Ltd

0.76%

Bill & Melinda Gates Foundation

0.70%

AQR Capital Management, LLC

0.44%

其他

95.06%

持股股東

佔比

Glazer Capital, LLC

2.02%

Alpine Associates Management Inc.

1.02%

Qube Research & Technologies Ltd

0.76%

Bill & Melinda Gates Foundation

0.70%

AQR Capital Management, LLC

0.44%

其他

95.06%

股東類型

持股股東

佔比

Hedge Fund

4.03%

Investment Advisor/Hedge Fund

2.87%

Investment Advisor

1.64%

Research Firm

0.89%

Foundation

0.70%

Pension Fund

0.16%

Bank and Trust

0.13%

Individual Investor

0.09%

Sovereign Wealth Fund

0.05%

其他

89.45%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

242

23.52M

11.47%

+45.36K

2025Q3

254

23.47M

13.08%

+8.57M

2025Q2

251

14.62M

11.55%

+3.90M

2025Q1

235

10.71M

11.20%

-14.51M

2024Q4

236

10.78M

11.68%

-1.77M

2024Q3

244

12.54M

12.61%

-3.08M

2024Q2

263

15.56M

13.23%

-3.38M

2024Q1

281

18.95M

13.33%

-10.95M

2023Q4

300

23.60M

17.13%

-11.99M

2023Q3

318

35.42M

18.08%

-1.78M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Glazer Capital, LLC

594.85K

0.26%

+594.85K

Jun 30, 2025

Alpine Associates Management Inc.

1.97M

0.88%

+1.97M

Jun 30, 2025

Qube Research & Technologies Ltd

1.18M

0.53%

+1.18M

Jun 30, 2025

Bill & Melinda Gates Foundation

1.57M

0.7%

-28.77K

-1.80%

Sep 30, 2024

Water Island Capital, LLC

957.03K

0.42%

+957.03K

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

580.38K

0.26%

-17.75K

-2.97%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AltShares Merger Arbitrage ETF

1.3%

Virtus LifeSci Biotech Clinical Trials ETF

0.65%

NYLI Merger Arbitrage ETF

0.57%

Global X Genomics & Biotechnology ETF

0.56%

ProShares Ultra Nasdaq Biotechnology

0.15%

Invesco Nasdaq Biotechnology ETF

0.11%

SPDR S&P International Small Cap ETF

0.05%

iShares Biotechnology ETF

0.04%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

AltShares Merger Arbitrage ETF

佔比1.3%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.65%

NYLI Merger Arbitrage ETF

佔比0.57%

Global X Genomics & Biotechnology ETF

佔比0.56%

ProShares Ultra Nasdaq Biotechnology

佔比0.15%

Invesco Nasdaq Biotechnology ETF

佔比0.11%

SPDR S&P International Small Cap ETF

佔比0.05%

iShares Biotechnology ETF

佔比0.04%

iShares MSCI Europe Small-Cap ETF

佔比0.04%

iShares MSCI EAFE Small-Cap ETF

佔比0.02%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

CureVac NV的前五大股東是誰？



CureVac NV的前五大股東如下：
Glazer Capital, LLC
持有股份：594.85K
佔總股份比例：0.26%。
Alpine Associates Management Inc.
持有股份：1.97M
佔總股份比例：0.88%。
Qube Research & Technologies Ltd
持有股份：1.18M
佔總股份比例：0.53%。
Bill & Melinda Gates Foundation
持有股份：1.57M
佔總股份比例：0.70%。
Water Island Capital, LLC
持有股份：957.03K
佔總股份比例：0.42%。